NFE2L2 and arthritic joint disease: Prior to further development of Cant as a new anti-RA drug in clinical studies, extensive evaluation is required regarding several key aspects: the detailed mechanisms by which Cant affects Nrf2 expression and ROS accumulation in macrophages; its potential effect on multiple species of animal models of arthritis; and its potential in in vivo toxicities for various organs.